Editas Medicine, Inc.

EDITNasdaq· Biological Products, (No Diagnostic Substances)

Price History

Revenue

$40.5M

▲ 25.4% YoY

Net Income

-$160.1M

▲ 32.5% YoY

EPS

$-1.80

▲ 37.5% YoY

Cash

$146.6M

▲ 11.5% YoY

FY 2025 · As of 2025-12-31

Pro

10-K Year-over-Year Diff

AI-powered analysis of what changed between the last two annual reports — new risks, removed language, strategy shifts.